LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
LIFECORE BIOMEDICAL, INC. DE
Financials through Q4 FY2025, quarter ended May 25, 2025Last filing: 10-Q on Aug 5, 2026
$6.39+0.01 (+0.16%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
LIFECORE BIOMEDICAL, INC. DE revenue by segment
By business segment
| Revenue | Q2 27 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $34.17M | $31.11M | $36.44M | $35.15M | – | $24.71M | – | – | – | – | – | – | 100.0% |
| Other | – | – | – | – | – | – | – | – | – | – | – | $0 | – |
| Curation Foods | – | – | – | – | – | – | – | – | – | – | – | $1.27M | – |
| Lifecore | – | – | – | – | – | – | – | – | – | – | – | $26.33M | – |
By product or service
| Revenue | Q2 27 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HA manufacturing | $18.62M | $9.36M | $12.93M | $14.37M | $6.95M | $4.53M | $8.79M | $13.40M | $6.47M | $2.98M | – | – | 54.5% |
| CDMO | $15.55M | $21.75M | $23.52M | $20.79M | $25.61M | $20.18M | $29.09M | $22.31M | $23.68M | $21.54M | $23.89M | $18.02M | 45.5% |
| Contract development and manufacturing organization and Fermentation | – | – | – | – | – | – | – | – | – | – | – | $26.54M | – |
| Fermentation | – | – | – | – | – | $4.53M | – | $13.40M | – | $2.98M | $7.26M | $8.52M | – |
| Avocado Products | – | – | – | – | – | – | – | – | – | – | – | $0 | – |
| Other | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – |
By region
| Revenue | Q2 27 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All other countries | – | – | – | – | – | – | – | – | – | – | – | $200.00K | – |
| Canada | – | – | – | – | – | – | – | – | – | – | – | $700.00K | – |
| Ireland | – | – | – | – | – | – | – | – | – | – | – | $1.10M | – |
| United Kingdom | – | – | – | – | – | – | – | – | – | – | – | $600.00K | – |
| Switzerland | – | – | – | – | – | – | – | – | – | – | – | $6.80M | – |
| Czechia | – | – | – | – | – | – | – | – | – | – | – | $700.00K | – |
| Australia | – | – | – | – | – | – | – | – | – | – | – | $1.10M | – |
From the segment and revenue-disaggregation notes of Lifecore Biomedical, Inc. De's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.